Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.84

+1.8%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4421)	8/8/2001 1:29:57 AM
From: tuck	Read Replies (1) of 52153

Tuck's rant of the day, kinda on topic . . . from my own post on Trickle re QGENF: >>Analysts getting more realistic? R.W. Baird's Larry Nabor upgrades the stock to strong buy and lowers the price target to $31 based on a more reasonable P/E multiple.<< Contrast today's treatment of QGENF with that of PRGX. Progenix today was downgraded by Scott Stromatt of CE Unterburg Tobin to buy from strong buy, but he raised the target. HuH? I rephrase my opening question: Are analysts looking more realistic or looking more silly in "correcting" their unrealities of the past? At least a few of them can ask intelligent questions about tool companies . . . One wonders why the rest get paid. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next